ClinicalTrials.gg
RecruitingNCT07776522Updated Aug 20, 2026

Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration

A Phase 2 interventional study of JWK001 and Aflibercept (2.0 mg) in Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD, sponsored by West China Hospital. Recruiting at 16 sites in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by West China Hospital · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
50th of 91
50 · median 62
Started
2026
with 7 others
Phase 2
14 of 106
4 open now
Primary completion
2027-08
later than 31 of 42 live
Registered
106th of 106
by date

Among the 106 studies in Macular Degeneration with a site in China, this one is the 50th largest by planned enrollment of the 91 interventional ones that give a count, is one of 8 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 31 of the 42 other live ones, and was the 106th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This is a Phase II, randomized, open-label, active-controlled study designed to evaluate the preliminary efficacy and safety of a single subretinal administration of JWK001 at different dose levels in patients with neovascular age-related macular degeneration.

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written and ability to comply with the study protocol.
  2. Male or female, aged 50-85 years.
  3. Active subfoveal MNV secondary to nAMD requiring anti-VEGF treatment.
  4. Demonstrated clinical response to aflibercept treatments in the study eye confirmed by the Reading Center;
  5. Study-eye BCVA of 19-78 ETDRS letters.
  6. Pseudophakic study eye.

Exclusion criteria

Exclusion Criteria:

  1. Any ocular condition other than nAMD that may affect vision, study assessments, treatment safety, or interpretation of results.
  2. Intraocular surgery or intraocular treatment within 4 weeks at screening.
  3. Any ocular condition making the study eye unsuitable for subretinal injection.
  4. Active ocular infection or inflammation, or a history of idiopathic or uveitis.
  5. Monocular status or non-study-eye BCVA \<19 ETDRS letters.
  6. systemic disease or infection, , prohibited concomitant treatment, prior gene therapy, or recent participation in another clinical trial.
  7. Any other condition considered by the investigator to make the subject unsuitable for participation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    JWK001 3×10^10 vg/eye group

    Participants assigned to this arm will receive a single subretinal injection of JWK001 at a dose of 3 × 10\^10 vector genomes (vg) in one study eye.

    Drug: JWK001

  • Experimental
    JWK001 6×10^10 vg/eye group

    Participants assigned to this arm will receive a single subretinal injection of JWK001 at a dose of 6 × 10\^10 vector genomes (vg) in one study eye.

    Drug: JWK001

  • Active comparator
    Aflibercept Active Comparator Group

    Participants assigned to this arm will receive aflibercept 2 mg by intravitreal injection at Weeks 2, 10, 18, 26, 34, 42, and 50 after randomization.

    Drug: Aflibercept (2.0 mg)

Interventions

  • DrugJWK001

    JWK001 will be administered as a single subretinal injection in one study eye.

  • Aflibercept 2 mg will be administered by intravitreal injection at Weeks 2, 10, 18, 26, 34, 42, and 50 after randomization, for a total of seven injections.

06

What researchers measure

Primary outcomes

  1. Change from baseline in best-corrected visual acuity (BCVA)

    BCVA measured via the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score

    Time frame: Week 34

Secondary outcomes

  1. Change from baseline in BCVA

    BCVA measured via the ETDRS letter score

    Time frame: Week 50 and Year 5

  2. Change from baseline in central retinal thickness (CRT)

    Time frame: Week 34, Week 50 and Year 5

  3. Change from baseline in the area of Macular Neovascularization (MNV)

    MNV measured via Fluorescein Angiography (FFA)

    Time frame: Week 34 and Week 50

  4. Change from baseline in leakage area

    Leakage area assessed by FFA

    Time frame: Week 34 and Week 50

  5. Annualized mean number of rescue treatments

    Time frame: Week 34, Week 50 and Year 5

  6. Change from baseline in the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) score

    NEI VFQ-25 composite score ranges from 0 to 100. Higher scores indicate better vision-related functioning and quality of life. A positive change from baseline indicates improvement, whereas a negative change indicates worsening.

    Time frame: Week 34 and Week 50

  7. Frequencies and severities of all safety events

    Time frame: Week 34 and Year 5

Other outcomes

  1. Neutralizing Antibodies (NAbs) Titer Against the Adeno-Associated Virus Serotype 8(AAV8) Capsid

    NAbs titer against the AAV8 capsid protein will be assessed in blood samples. Higher titers indicate a stronger neutralizing antibody response.

    Time frame: Week 50

  2. Anti-Drug Antibody (ADA) Titer Against the nVEGF1 Protein

    ADA titers against the nVEGF1 protein expressed by JWK001 will be measured in blood samples. Higher titers indicate a stronger anti-drug antibody response.

    Time frame: Week 50

  3. T-Cell Immune Response Against the AAV8 Capsid Protein

    T-cell immune responses against the AAV8 capsid protein will be assessed using an enzyme-linked immunospot (ELISpot) assay.

    Time frame: Week 50

  4. T-Cell Immune Response Against the nVEGF1 Protein

    T-cell immune responses against the nVEGF1 protein will be assessed using an enzyme-linked immunospot (ELISpot) assay.

    Time frame: Week 50

  5. JWK001 Vector DNA Level in Blood

    JWK001 vector DNA will be measured in blood samples.

    Time frame: Week 4

  6. JWK001 Vector DNA Level in Tears

    JWK001 vector DNA will be measured in tear samples

    Time frame: Week 4

  7. JWK001 Vector DNA Level in Urine

    JWK001 vector DNA will be measured in urine samples

    Time frame: Week 4

  8. JWK001 Vector DNA Level in Feces

    JWK001 vector DNA will be measured in fecal samples

    Time frame: Week 4

  9. Concentration of the nVEGFi Transgene Expression Product in Blood

    The concentration of the nVEGFi transgene expression product will be measured in blood samples

    Time frame: Week 50

  10. Concentration of the nVEGFi Transgene Expression Product in Aqueous Humor

    The concentration of the nVEGFi transgene expression product will be measured in aqueous humor samples

    Time frame: Week 104

07

Study locations

2 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2027, 11 months later.

Of 83 phase 2 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 35. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2026
First posted
Aug 20, 2026
StartEst.
Aug 31, 2026
Primary completionEst.
Aug 15, 2027
CompletionEst.
Jan 14, 2032
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07776522
Responsible party
Fang Lu (Professor and Chief Physician, West China Hospital) — Principal investigator
First posted
Aug 20, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Aug 15, 2027 (estimated)
Completion
Jan 14, 2032 (estimated)
Last update
Aug 20, 2026

Study contacts

Lu
Contact
lufang@wchscu.cn
86-0288542538

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion